| ◆15th | In supporting studies of drug seeds from academiaNEW Hiroshi Sumichika, Ph.D. (Drug Development Service Segment, Advanced Medical Business Development Department, LSI Medience Corporation) |
| ◆14th | Practical Application of Research Results by Drug Discovery and Development Carve-outNEW Tohru Yoshikawa (Director & Secretary General, Bio New Combinations Research Institute) |
| ◆13th | Discovery of new drug discovery targets for African trypanosomiasis (African sleeping sickness)- Trypanosoma-Specific Allosteric Regulation Mechanisms by GMP Reductase -NEW Takashi Inui (Professor, Graduate School of Life and Environmental Sciences, Osaka Prefecture University) |
| ◆12th | Comming Soon |
| ◆11th | Efforts to Standardize Real World Data Satomi Nagashima (Project Researcher, Department of Healthcare Information Management, University of Tokyo Hospital) |
| ◆10th | Accelerating Commercialization of Drug Discovery Seeds through Sharing of Research and Business Roles Takashi Nakaoka (Manager, Beyond Next Ventures, Inc.) |
| ◆9th | Development of an in vitro assay to evaluate higher brain functions for drug discovery Noriko Koganezawa and Tomoaki Shirao (Department of Neurobiology and Behavior, Gunma University Graduate School of Medicine) |
| ◆8th | Participation in DISC Business with Miniaturized HTS as a Bridge Kenji Wakabayashi, Ph.D. (Vice President, Biological Research Department, Daiichi Sankyo RD Novare Co., LTD.) |
| ◆7th | Cell Therapy and Drug Discovery Research based on Next-Generation Gene Transfer Technology / Artificial Chromosome Vectors Yasuhiro Kazuki, Ph.D. (Associate Professor, Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Chromosome Engineering Research Center (CERC) Director, Tottori Pharmaceutical Innovation Center (TPIC) ) |
| ◆6th | Challenges to "Reverse Value Generation" Drug Discovery Hiroshi Nagabukuro, Ph.D. (COO/CSO, ARTham Therapeutic/ Adjunct Professor, Oita University, Faculty of Medicine, Department of Clinical Pharmacology & Therapeutics) |
| ◆5th | Small Biotech with a Big Vision Masaaki Sawa, Ph.D. (Chief Scientific Officer, CARNA BIOSCIENCES, INC.) |
| ◆4th | Development of Nasal Drug Delivery System = Translational Research Business Shuichi Kanazashi, Ph.D. (President, Shin Nippon Biomedical Laboratories, Ltd.) |
| ◆3rd | SEND, FDA, and Industry Movement Takayuki Anzai (Professor (AP), Showa University, School of Medicine) |
| ◆2nd | Drug Discovery in Academia – Initiatives by NIBIOHN Yoshihiro Yoneda (Director General, National Institutes of Biomedical Innovation, Health and Nutrition) |
| ◆1st | Aspiring to be a Navigator of Innovative Drug Discovery Development Noriatsu Kono (Managing Director, Department of Innovative Drug Discovery and Development, Japan Agency for Medical Research and Development) |
| ◆1st | Current Vaccine Drug Discovery and What We Need to Consider NowNEW Ken Ishii (Professor, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo) |
